1-3 of 3
Christine A. White
Close
Sort by
Journal Articles

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20 + B-cell lymphoma: long-term follow-up of a phase 1/2 study

Clinical Trials & Observations Brief Report
Leo I. Gordon, Arturo Molina, Thomas Witzig, Christos Emmanouilides, Andrew Raubtischek, Mohamed Darif, Russell J. Schilder, Greg Wiseman, Christine A. White
Journal: Blood
Blood (2004) 103 (12): 4429–4431.
https://doi.org/10.1182/blood-2003-11-3883
Published: 2004
Journal Articles

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial

Clinical Trials & Observations
Gregory A. Wiseman, Leo I. Gordon, Pratik S. Multani, Thomas E. Witzig, Stewart Spies, Nancy L. Bartlett, Russell J. Schilder, James L. Murray, Mansoor Saleh, Roberta S. Allen, Antonio J. Grillo-López, Christine A. White
Journal: Blood
Blood (2002) 99 (12): 4336–4342.
https://doi.org/10.1182/blood.V99.12.4336
Published: 2002
Journal Articles

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

David G. Maloney, Antonio J. Grillo-López, Christine A. White, David Bodkin, Russell J. Schilder, James A. Neidhart, Nalini Janakiraman, Kenneth A. Foon, Tina-Marie Liles, Brian K. Dallaire, Ken Wey, Ivor Royston, Thomas Davis, Ronald Levy
Journal: Blood
Blood (1997) 90 (6): 2188–2195.
https://doi.org/10.1182/blood.V90.6.2188
Published: 1997